Recognition of SARS-CoV-2 variants of concern
We have previously produced a number of RBD’s variants, including the UK, Brazilian and Indian VOC (29, 30) and shown, as others, that mutations at position E484K strongly reduce recognition by convalescent sera (30, 31). It is therefore of significant interest that our vaccine induced immune sera recognized all variant RBDs equally well as the wild type RBD (Fig 4A and B). Hence, this vaccine candidate may have the potential to protect against all VoC that occurred up to now equally well.